12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Company News  |  Other News

La Jolla Pharmaceutical pharmaceuticals news

La Jolla said it is seeking to in-license or acquire small molecules indicated for cancer, dermatology, gastrointestinal diseases, rare or orphan diseases and infectious diseases, excluding HIV, HCV and HBV. The company expects to complete candidate identification by Sept. 30. La Jolla, which started a...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >